Bruker Reports Fourth Quarter and Full Year 2023 Financial Results

Go back to Bruker Reports Fourth Quarter and Full Year 2023 Financial Results

JPMorgan Upgrades Bruker (BRKR) to Overweight

February 13, 2024 4:24 PM EST

JPMorgan analyst Tycho W. Peterson upgraded Bruker (NASDAQ: BRKR) from Neutral to Overweight with a price target of $90.00 (from $60.00).

The analyst comments "This morning, Bruker (BRKR) reported a sizeable 4Q beat while initiating better-than-expected 2024 guidance and, most notably, pulled forward its 2026 revenue and non-GAAP EPS LRP targets to 2025 (implying >30% non-GAAP EPS growth in 2025). Strength across regions and end-markets is driven by secular trends in proteomics and other omics research in what the company describes as the... More

Bruker (BRKR) Tops Q4 EPS by 2c

February 13, 2024 7:03 AM EST

Bruker (NASDAQ: BRKR) reported Q4 EPS of $0.70, $0.02 better than the analyst estimate of $0.68. Revenue for the quarter came in at $854.4 million versus the consensus estimate of $803.81 million.

For earnings history and earnings-related data on Bruker (BRKR) click here.

... More